Alanosine

Alanosine (also called SDX-102)[1] is a substance that has been studied for the treatment of pancreatic cancer.[2] It is an antimetabolite. It is used as one of a few experimental treatments for patients with deadly pancreatic cancer when the main chemotherapeutic treatment regimen of gemcitabine is no longer useful.

Alanosine
Clinical data
ATC code
  • None
Identifiers
IUPAC name
  • (S)-2-Amino-3-[hydroxy(nitroso)amino]propanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC3H7N3O4
Molar mass149.106 g·mol−1
3D model (JSmol)
SMILES
  • O=C(O)[C@@H](N)CN(O)N=O
InChI
  • InChI=1S/C3H7N3O4/c4-2(3(7)8)1-6(10)5-9/h2,10H,1,4H2,(H,7,8)/t2-/m0/s1 Y
  • Key:MLFKVJCWGUZWNV-REOHCLBHSA-N Y
  (verify)

References
  1. PubChem. "Alanosine". pubchem.ncbi.nlm.nih.gov. Retrieved 2021-04-08.
  2. Yu J (November 2001). "Alanosine (UCSD)". Current Opinion in Investigational Drugs. 2 (11): 1623–30. PMID 11763167.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.